These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 21262381)

  • 61. [RhoJ signaling pathway in retinal angiogenesis: promising targets for novel anti-angiogenic therapy].
    Fukushima Y
    Nippon Ganka Gakkai Zasshi; 2013 Nov; 117(11):903-10. PubMed ID: 24397187
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Review of selected patents for cancer therapy targeting tumor angiogenesis.
    Kirstein MN; Moore MM; Dudek AZ
    Recent Pat Anticancer Drug Discov; 2006 Jun; 1(2):153-61. PubMed ID: 18221033
    [TBL] [Abstract][Full Text] [Related]  

  • 63. VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).
    Peng FW; Liu DK; Zhang QW; Xu YG; Shi L
    Expert Opin Ther Pat; 2017 Sep; 27(9):987-1004. PubMed ID: 28621580
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Vessel pruning or healing: endothelial metabolism as a novel target?
    Cantelmo AR; Pircher A; Kalucka J; Carmeliet P
    Expert Opin Ther Targets; 2017 Mar; 21(3):239-247. PubMed ID: 28081641
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Tumor angiogenesis and anti-angiogenic therapy.
    Kubota Y
    Keio J Med; 2012; 61(2):47-56. PubMed ID: 22760023
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Approaches of targeting Rho GTPases in cancer drug discovery.
    Lin Y; Zheng Y
    Expert Opin Drug Discov; 2015; 10(9):991-1010. PubMed ID: 26087073
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Current status of cediranib: the rapid development of a novel anti-angiogenic therapy.
    Lindsay CR; MacPherson IR; Cassidy J
    Future Oncol; 2009 May; 5(4):421-32. PubMed ID: 19450171
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Antiangiogenic Effect of Flavonoids and Chalcones: An Update.
    Mirossay L; Varinská L; Mojžiš J
    Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29271940
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Angiogenesis in spontaneous tumors and implications for comparative tumor biology.
    Benazzi C; Al-Dissi A; Chau CH; Figg WD; Sarli G; de Oliveira JT; Gärtner F
    ScientificWorldJournal; 2014; 2014():919570. PubMed ID: 24563633
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Mechanisms that influence tumour response to VEGF-pathway inhibitors.
    Smith NR; Wedge SR; Pommier A; Barry ST
    Biochem Soc Trans; 2014 Dec; 42(6):1601-7. PubMed ID: 25399577
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The great escape; the hallmarks of resistance to antiangiogenic therapy.
    van Beijnum JR; Nowak-Sliwinska P; Huijbers EJ; Thijssen VL; Griffioen AW
    Pharmacol Rev; 2015; 67(2):441-61. PubMed ID: 25769965
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Modes of resistance to anti-angiogenic therapy.
    Bergers G; Hanahan D
    Nat Rev Cancer; 2008 Aug; 8(8):592-603. PubMed ID: 18650835
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Therapeutic options to target angiogenesis in human malignancies.
    Herbst RS
    Expert Opin Emerg Drugs; 2006 Nov; 11(4):635-50. PubMed ID: 17064223
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Rho GTPases and cancer.
    Li H; Peyrollier K; Kilic G; Brakebusch C
    Biofactors; 2014; 40(2):226-35. PubMed ID: 24375503
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Role of tumor vascular architecture in drug delivery.
    Narang AS; Varia S
    Adv Drug Deliv Rev; 2011 Jul; 63(8):640-58. PubMed ID: 21514334
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Current data on predictive markers for anti-angiogenic therapy in thoracic tumours.
    Reinmuth N; Thomas M; Meister M; Schnabel PA; Kreuter M
    Eur Respir J; 2010 Oct; 36(4):915-24. PubMed ID: 20889462
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Anti-Angiogenic Therapy: Current Challenges and Future Perspectives.
    Lopes-Coelho F; Martins F; Pereira SA; Serpa J
    Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33916438
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Targeting survivin in cancer: the cell-signalling perspective.
    Kanwar JR; Kamalapuram SK; Kanwar RK
    Drug Discov Today; 2011 Jun; 16(11-12):485-94. PubMed ID: 21511051
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Inhibitors of Angiogenesis in Cancer Therapy - Synthesis and Biological Activity.
    Gensicka M; Głowacka A; Dzierzbicka K; Cholewinski G
    Curr Med Chem; 2015; 22(33):3830-47. PubMed ID: 26337104
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Glycosylation as new pharmacological strategies for diseases associated with excessive angiogenesis.
    Bousseau S; Vergori L; Soleti R; Lenaers G; Martinez MC; Andriantsitohaina R
    Pharmacol Ther; 2018 Nov; 191():92-122. PubMed ID: 29909237
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.